BIOTECH CATALYST AI SCANNER — APRIL WK4 2026

Alex

17 Apr 2026 — 26 min read

(Editor's Note) I’ve slightly updated the AI Scanner to provide more detailed information about each ticker, especially for the Top 10 Picks. While this doesn’t guarantee improved predictions, I hope it enhances your understanding of each ticker before conducting your own due diligence. If you find this article excessively long or if the new approach compromises readability, please leave a comment.

I’ve also attempted to expand the catalyst window to 90 days, but it didn’t make any significant difference in the results. The machine learning algorithm automatically prioritizes catalysts that are more imminent. As a reminder, this scanner scans expected catalyst events that are likely to occur within the next 45 days and attempts to identify opportunities for significant price movements. However, it’s important to recognize that holding a position through catalysts is an extremely risky investment strategy. Due diligence and an appropriate investment strategy are crucial for managing your risk.

Conference season is compressing the calendar. Between now and June 2, the scan covers events at DDW, ATS, ISPOR, ASCO, ISSVA, ARVO, ASGCT, and ICAR — a back-to-back stretch where data readouts arrive faster than they can be fully digested. Catalyst-driven small-caps tend to move on abstracts before the conference presentation even lands, which is worth keeping in mind when sizing entries. The XBI has recovered off its late-March lows but remains below its 200-day moving average, and macro jitters around tariff policy have kept risk appetite in small-cap biotech measured. Sector rotation into large-cap defensives is a headwind for the names below $100M in market cap — and there are several of those in this issue.

The dominant theme this week is the PDUFA cluster building into late May. Two FDA decision dates — MNKD on May 29 and CING on May 31 — arrive within 48 hours of each other, both pediatric applications with meaningful commercial optionality. EDSA stands apart from everything else in the scan: it entered April as the only company with a positive Phase 3 trial in acute respiratory distress syndrome (ARDS), and the market has largely ignored it. Meanwhile, RLAY has run 62% in three weeks, is sitting on two months of cash, and its May catalyst is a 20-patient initial dataset in an orphan indication — a mismatch worth noting before chasing momentum.

The scoring spread this week is meaningful. MNKD at BSI 8.55 reflects a genuinely de-risked setup: approved drug, Phase 3 pediatric data in hand, FDA PDUFA date set, long runway. The bottom of the featured list sits in the 7.3–7.4 range, where legitimate science coexists with real structural constraints — thin runway, small trial Ns, conference presentations rather than pivotal readouts, or crowded competitive fields. Read the Risk sections carefully on the lower-scored entries. They're specific for a reason.

What We're Tracking:

Trading Below Cash: BIVI
Cash Pressure: PSTV, JAGX, RLAY, COCP
Initial Data: RLAY, BIVI, CLYM
Multi-Catalyst: None this week

FEATURED — #1 through #10

#1. MNKD — MannKind Corporation

THE CATALYST
Event: Afrezza (Technosphere Insulin) — PDUFA Regulatory Decision in Pediatric Type 1/2 Diabetes
Date: May 29, 2026
BSI: 8.55/10

MannKind is a Connecticut-based specialty pharma company with an approved inhaled insulin franchise and a diversifying pipeline. The United Therapeutics partnership for Tyvaso DPI (inhaled treprostinil for pulmonary hypertension) generates royalty revenue off the same Technosphere dry-powder delivery platform that underpins Afrezza. In October 2025, MannKind acquired scPharmaceuticals, adding Furoscix (subcutaneous furosemide for outpatient heart failure edema) and its own PDUFA event later in the year. Blackstone committed up to $500M in non-dilutive financing to fund the integration.

📈 The Setup: No inhaled insulin has ever been approved for children — NovoLog and Humalog are the injectable standards, and roughly 40% of pediatric type 1 patients report needle anxiety as a genuine adherence barrier. Afrezza delivers human insulin as Technosphere dry-powder particles that dissolve in the lung within 12 minutes, faster than any injected rapid-acting analog. In INHALE-1 (N=230 patients aged 4–17), Afrezza achieved noninferior HbA1c control (glycated hemoglobin, the standard three-month blood sugar measure) at 26 weeks versus injected analogs, with no difference in FEV1 (forced expiratory volume, a measure of lung function). FDA accepted that 26-week window as the primary bar — already a call made in MannKind's favor. The market is crediting adult Afrezza's $200M+ annualized trajectory but discounting the pediatric label, skepticism partly driven by a 52-week extension showing +0.46% HbA1c drift in the Afrezza arm while the injection group held flat. That durability gap wasn't the primary endpoint, but it will be in every reviewer's read heading into May 29.

✅ The Edge: First-mover exclusivity in pediatric inhaled insulin. FDA sBLA acceptance is the harder gatekeeping step, already cleared. The adult physician education, device simplicity, and payer contracting playbook is already operational and extends rather than rebuilds for a pediatric label.

⚠️ The Risk: Exubera's 2007 withdrawal — the only prior inhaled insulin, pulled after lung cancer signals in adult smokers — still shapes pediatric pulmonary safety scrutiny, and Afrezza's adult label already carries an FEV1 monitoring requirement. Pediatric payer access will mirror the adult rollout: step therapy requiring documented failure of injectable generics first.

#2. PSTV — PLUS THERAPEUTICS Inc.

THE CATALYST
Event: CNSide — Phase 1 Conference Presentation in Breast/NSCLC Leptomeningeal Metastases
Date: May 17, 2026
BSI: 8.15/10

Houston-based Plus Therapeutics develops targeted radiotherapeutics and diagnostics for CNS cancers. Its lead therapeutic, REYOBIQ (rhenium-186 nanoparticle radiotherapy delivered directly into the cerebrospinal fluid), is advancing in Phase 1 for leptomeningeal metastases (LM; cancer that has spread to the membranes surrounding the brain and spinal cord). The company acquired its LM assets in May 2024, completed a $15M equity raise in January 2026, and executed a 1-for-25 reverse split in March 2026 to regain Nasdaq compliance. Payer agreements covering 75 million lives — including UnitedHealthcare, Humana, and Highmark — are already in place for the CNSide diagnostic.

📈 The Setup: Standard CSF cytology (examining cancer cells in spinal fluid) detects LM with only 25–30% sensitivity — it misses the majority of early-stage cases. CNSide is a liquid biopsy assay that enumerates circulating tumor cells in CSF, tracks targetable mutations including PIK3CA (a gene alteration driving abnormal cell growth) and EGFR (a receptor overexpressed in certain lung and breast cancers) serially, and caught disease in 80% of cases where cytology came up empty. In the FORESEE trial (N=39 breast/NSCLC patients), CNSide influenced treatment decisions in 91% of cases versus a 20% target threshold. The ISPOR poster on May 17 isn't new efficacy data — it's a Harvard-co-authored cost-offset model projecting 33–47% savings in LM management costs through earlier detection. The 75-million-life payer coverage is infrastructure already in place; what hasn't followed is routine ordering by oncologists. This is a conference presentation, not a pivotal event: the outcome is a better economic narrative, not a binary approval trigger. With 8 months of runway, Plus needs that narrative to start moving the commercial needle.

✅ The Edge: CNSide's 80% sensitivity against cytology's 29% is detecting disease that standard-of-care misses entirely. The Harvard cost model translates that clinical advantage into a payer argument — LM hospitalizations run over $100K per month, and earlier detection reduces those downstream costs. Existing 75M-life contracts give the commercial infrastructure a head start that cfDNA CSF sequencing approaches (Massachusetts General pilots) don't yet have.

⚠️ The Risk: A health-economics model built partly on literature assumptions is only as strong as the methodology — peer scrutiny at ISPOR could undermine the cost savings argument before it reaches payer medical directors. CNSide operates as a laboratory-developed test (LDT), a category FDA began scrutinizing under 2024 lab reform rules. Eight months of runway with no reimbursement revenue yet flowing leaves very little room for a slow ramp.

#3. CING — Cingulate Inc.

THE CATALYST
Event: CTx-1301 — PDUFA Regulatory Decision in Pediatric ADHD
Date: May 31, 2026
BSI: 8.01/10

Cingulate is a Kansas City-based neuropsychiatric company built around its Precision Timed Release (PTR) platform — a multi-core tablet architecture that engineers timed drug pulses to maintain consistent plasma levels throughout the day. The company forged an exclusive manufacturing alliance with Bend Bio Sciences for commercial production. A $12M PIPE in February 2026 and a $100M at-the-market equity facility in March 2026 secure runway well past the PDUFA date regardless of outcome.

📈 The Setup: Down 34.6% over the past three weeks, RSI 31 — technically oversold heading into a PDUFA where the Phase 3 data is strong. CTx-1301 delivers dexmethylphenidate (the more potent isomer of methylphenidate, a CNS stimulant that elevates dopamine and norepinephrine) through three timed release layers in a single morning tablet: immediate onset, a midday pulse, and a late-day extension that stretches coverage to 16 hours. No approved stimulant achieves that window; Focalin XR peaks at 8–12 hours and Vyvanse, despite its duration claims, tapers meaningfully by late afternoon. In the pediatric Phase 3 (ages 6–17, fixed doses vs. placebo), CTx-1301 hit the primary ADHD-RS-5 (ADHD Rating Scale-5, a validated symptom score) endpoint with p<0.001 and effect sizes of 0.737 to 1.185 — that peak figure is top-tier for stimulants and was achieved with a fixed rather than optimized dose. The crowded landscape is the tension: Vyvanse generics, Adderall XR generics, and cheap Focalin XR generics have all arrived since the stimulant shortage eased. The $64M market cap is pricing commercial skepticism more than approval uncertainty.

✅ The Edge: CTx-1301 would be the only 16-hour once-daily stimulant on the market if approved, covering the coverage gap Focalin XR and Vyvanse leave open in the late afternoon. FDA accepted the NDA and the novel triphasic concept for review — the agency's willingness to engage on the PK profile is a meaningful signal.

⚠️ The Risk: The ADHD stimulant market is the most generic-saturated space in CNS psychiatry, and physicians have limited incentive to pay a brand premium when generics cover the school day adequately. Bend Bio Sciences' commercial-scale manufacturing is unproven beyond clinical lots, and FDA precedent includes advisory scrutiny on novel ADHD delivery systems translating from controlled trials to real-world ambulatory use.

#4. JAGX — Jaguar Health Inc.

THE CATALYST
Event: Crofelemer — Phase 2 Conference Presentation in Short Bowel Syndrome with Intestinal Failure
Date: May 05, 2026
FDA Status: Orphan Drug Designation (ODD)
BSI: 7.98/10

San Francisco-based Jaguar Health pivoted in January 2026 from its commercial Mytesi franchise after out-licensing U.S. rights to Future Pak for $16M upfront plus $3M in follow-on payments — non-dilutive capital that bought time for the DDW (Digestive Disease Week) readout despite a negative cash position. The company's focus is now orphan intestinal failure: SBS-IF (short bowel syndrome with intestinal failure; inadequate small intestine function requiring lifelong intravenous nutrition) and MVID (microvillus inclusion disease; a rare congenital disorder causing severe secretory diarrhea from infancy).

📈 The Setup: Sub-$6M market cap, negative cash, three months of runway — this is maximum binary pressure. Crofelemer is a plant-derived compound that inhibits CFTR and CaCC chloride channels (the ion pathways that drive fluid loss into the gut lumen), reducing hypersecretion without altering motility. The approved standard is Gattex (teduglutide, a GLP-2 analog that promotes intestinal mucosal growth), which achieves 20–30% reduction in TPN (total parenteral nutrition; the lifelong intravenous feeding required when the gut can't absorb enough nutrition). Crofelemer's mechanism is completely different — it targets the secretory side rather than the absorptive side — which makes it additive rather than competitive to Gattex, a meaningful positioning argument if the data holds. Prior expanded access pediatric data showed 12.5% TPN reduction in SBS-IF and 27% in MVID. The DDW abstract (May 2–5) will present Phase 2 adult data from an investigator-led trial. This is not a pivotal readout: small N, unblinded, investigator-led. The bar for beating zero — which is what $5.4M implies — is low, but the data quality constraints are real.

✅ The Edge: Orphan Drug Designation provides seven years of market exclusivity post-approval in this indication. The CFTR/CaCC mechanism is orthogonal to Gattex and apraglutide (Zealand Pharma/Ironwood's weekly GLP-2 in late-stage development), making crofelemer a logical add-on rather than a head-to-head challenger in a patient population with limited options.

⚠️ The Risk: The Phase 2 adult trial is investigator-led, small N, and unblinded — precisely the conditions where patient-level variability in residual bowel length, SBS etiology, and baseline TPN volumes can swamp a real biological signal. If the data misses, there is no visible bridge financing: three months of runway and an out-licensed commercial asset leave almost no recovery path.

#5. EDSA — Edesa Biotech Inc.

THE CATALYST
Event: Paridiprubart (EB05) — Phase 3 Conference Presentation in Acute Respiratory Distress Syndrome
Date: May 20, 2026
FDA Status: Fast Track Designation (FTD)
BSI: 7.97/10

Toronto-headquartered Edesa Biotech is a Canadian-domiciled, Nasdaq-listed company developing host-directed immunotherapies. Paridiprubart has attracted C$23 million in Canadian government funding for manufacturing scale-up and was selected by BARDA (the U.S. Biomedical Advanced Research and Development Authority) for a funded platform trial in general ARDS. A separate vitiligo program advances to Phase 2 mid-2026, and an allergic contact dermatitis Phase 2b is complete. The Phase 3 primary endpoint was confirmed hit in February 2026 across the full 278-patient cohort.

📈 The Setup: Paridiprubart is the only drug to produce a positive Phase 3 result in ARDS (acute respiratory distress syndrome; life-threatening lung failure driven by severe systemic inflammation) — a disease that kills roughly 75,000 Americans per year and has defeated every prior pharmacological attempt, including tocilizumab's lapsed COVID authorization. The mechanism is TLR4 inhibition: paridiprubart is a monoclonal antibody that blocks TLR4 (Toll-like receptor 4, an innate immune sensor that triggers the cytokine storm destroying lung tissue in ARDS), suppressing the inflammatory cascade upstream rather than managing its downstream consequences. In the Phase 3 trial (N=278), paridiprubart plus standard care cut 28-day mortality from 33% to 24% — a 27% relative risk reduction — and 60-day mortality from 59% to 46%. At $43M market cap and near-zero volume (0.04x), the market is applying heavy regulatory skepticism to a completed positive Phase 3. ATS May 20 will present the full mortality curves, subgroup analyses, and safety data. BARDA's selection for a general ARDS platform trial — independent of COVID — addresses the declining COVID-ARDS incidence concern by extending the program to 3 million annual global ICU cases.

✅ The Edge: No FDA-approved ARDS-specific drug exists. Paridiprubart enters ATS as the uncontested leader with a completed randomized trial and Fast Track Designation, plus non-dilutive BARDA funding that extends the program without a capital raise.

⚠️ The Risk: ATS subgroup analyses may reveal the mortality benefit is concentrated in ventilated COVID patients rather than generalizable to broader ARDS — a finding that complicates the NDA bridging argument. FDA has never approved a TLR4 inhibitor; the regulatory pathway requires the agency to validate a novel mechanism in a disease with no approved comparator, and the endpoint precedent is still being established.

#6. RLAY — Relay Therapeutics Inc.

THE CATALYST
Event: Zovegalisib (RLY-2608) — Initial Data Conference Presentation in PIK3CA-Mutant Vascular Anomalies
Date: May 20, 2026
FDA Status: Breakthrough Therapy Designation (BTD)
BSI: 7.87/10

Cambridge, Massachusetts-based Relay Therapeutics uses its Dynamo computational platform to design precision small molecules for oncology and genetic diseases. Zovegalisib's primary program is Phase 3 ReDiscover-2 in PIK3CA-mutant HR+/HER2- breast cancer. Breakthrough Therapy Designation was granted in February 2026, following Phase 1/2 data showing 11.1-month median progression-free survival in heavily pretreated patients. CFO share sales in April occurred alongside institutional buying.

📈 The Setup: Shares are up 62% in three weeks on BTD momentum and the breast cancer Phase 1/2 data — but the May 20 catalyst is not ReDiscover-2. It is the first-ever human data for zovegalisib in PIK3CA-driven vascular anomalies (rare malformations including CLOVES syndrome and PROS — PIK3CA-Related Overgrowth Spectrum — affecting roughly 10,000 U.S. patients), presented to approximately 20 efficacy-evaluable patients at ISSVA. Zovegalisib selectively inhibits mutant PI3Kα (phosphatidylinositol 3-kinase alpha, an enzyme activated by PIK3CA gene mutations to drive uncontrolled cell growth), avoiding the hyperglycemia that non-selective PI3Kα inhibitors like alpelisib produce from pancreatic on-target effects. The breast cancer Phase 1/2 delivered 43% objective response rate alongside the 11.1-month PFS. The vascular anomaly data is optionality — meaningful if it shows lesion reduction, but the ReDiscover-2 Phase 3 remains the value driver. The structural concern is independent of the May 20 catalyst: $2.88B market cap, two months of cash. A capital raise before summer is not optional.

✅ The Edge: The only mutant-selective PI3Kα inhibitor in a Phase 3 randomized trial, with BTD. Mutant selectivity removes the hyperglycemia barrier that has limited real-world alpelisib adoption despite approval, enabling chronic dosing combinations. No approved targeted therapy exists for PIK3CA-mutant vascular anomalies.

⚠️ The Risk: Twenty efficacy-evaluable patients in a heterogeneous population is a dataset that can move in either direction based on a handful of outlier responders. The capital raise that must happen before summer will be sized against the current momentum price — if it occurs post-catalyst on weakness, the dilution is larger. Roche's inavolisib is entering a Phase 3 triplet in the same breast cancer indication.

#7. CRBP — Corbus Pharmaceuticals Holdings Inc.

THE CATALYST
Event: CRB-701 — Phase 1/2 Monotherapy Update at ASCO in 2L HNSCC / Cervical Cancer / mUC
Date: May 30, 2026
BSI: 7.75/10

Norwood, Massachusetts-based Corbus holds an exclusive license for CRB-701 from CSPC Megalith Biopharmaceutical for territories outside China. A separate obesity program (CRB-913, a CB1 receptor modulator) is in Phase 2. On April 7, 2026, FDA confirmed alignment on CRB-701's registrational study design and endpoints for accelerated approval in second-line HNSCC (head and neck squamous cell carcinoma; cancer of the mouth, throat, and upper airway lining) and cervical cancer — the underappreciated event that defines this entry.

📈 The Setup: The April 7 FDA meeting is the core signal here. The agency explicitly accepted ORR (objective response rate; proportion of patients with measurable tumor shrinkage) as the primary endpoint for single-arm registrational trials in these indications — the same framework that carried enfortumab vedotin (Padcev, a Nectin-4 ADC for urothelial carcinoma) to accelerated approval without a randomized Phase 3. CRB-701 is a Nectin-4-directed ADC (antibody-drug conjugate; a targeted antibody carrying cytotoxic payload directly to tumor cells expressing Nectin-4, a cell surface protein overexpressed across multiple solid tumors). In ESMO Phase 1/2 data (October 2025, 122 evaluable patients), the 3.6 mg/kg dose produced ORRs of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in metastatic urothelial carcinoma — against second-line chemotherapy ORRs of roughly 10–14% in HNSCC. At $179.8M cap with $144.3M cash, the enterprise value is approximately $35M on a program with FDA-aligned registrational endpoints. ASCO will update the Phase 1/2 dataset with a longer data cut.

✅ The Edge: FDA's explicit endorsement means Corbus can move directly from an expanded Phase 1/2 to an NDA filing using ORR — compressing the timeline by two to three years versus a traditional randomized Phase 3. No other Nectin-4 ADC has reached registrational alignment with FDA in HNSCC or cervical cancer; Bicycle Therapeutics' BT8009 and Mabwell's MW323 are earlier stage.

⚠️ The Risk: ASCO's expanded cohort could dilute the headline ORRs as the denominator grows — a pattern common when dose-expansion response rates are recalculated with additional patients. Grade 3+ interstitial lung disease (ILD; lung inflammation, an ADC class-effect toxicity) rates may not have peaked in one year of follow-up. Post-Keytruda combination data in frontline HNSCC will pressure monotherapy ADC positioning over time.

#8. WVE — Wave Life Sciences Ltd.

THE CATALYST
Event: WVE-006 — Phase 1b/2 Interim Data at ATS in AATD PiZZ Homozygous Patients
Date: May 18, 2026
BSI: 7.45/10

Cambridge, Massachusetts-based Wave Life Sciences is Singapore-domiciled, with U.S. redomiciliation in process. Its GSK collaboration selected a fourth development candidate in January 2026. Wave reacquired full global rights to WVE-006 from GSK to accelerate regulatory discussions — a signal that the partnership structure was slowing development, not that the program is weak.

📈 The Setup: Beam Therapeutics set the current AATD benchmark in March 2026: BEAM-302 (an IV base-editing gene therapy) showed durable total AAT elevations above 10µM and Z-AAT reductions exceeding 90% in Phase 1/2, sending shares up 50%. WVE-006 is the repeat-dose subcutaneous alternative. It is a GalNAc-conjugated RNA editing oligonucleotide (a liver-targeted molecule that uses natural RNA editing machinery to rewrite the disease-causing SERPINA1 PiZ mRNA into the normal PiM sequence), restoring functional M-AAT protein while simultaneously reducing toxic, aggregating Z-AAT protein in PiZZ homozygous patients — attacking the same root cause as a gene therapy but via a reversible, re-dosable approach. Prior 200mg multidose data showed 7.2µM M-AAT restored and 60% Z-AAT reduction — meaningful but below Beam's single-session numbers. ATS will present the 400mg and 600mg multidose cohorts: the question is whether higher doses close the gap or plateau. The stock is down 38.5% over three weeks despite $561.9M in cash. At 50 months of runway, Wave can afford to wait for the data to build.

✅ The Edge: Subcutaneous dosing gives WVE-006 a real-world administration advantage over Beam-302's IV infusion for a condition requiring lifelong monitoring and dose adjustments. Unlike weekly IV augmentation therapies (Prolastin-C, Aralast NP), WVE-006 addresses the liver Z-AAT aggregation that augmentation doesn't touch. GSK's fourth candidate selection validates the platform beyond AATD.

⚠️ The Risk: GalNAc-RNA editing has no approved precedents — FDA may require liver biopsy histology or multi-year functional endpoints rather than accepting M-AAT protein levels as a regulatory surrogate. Beam-302's durable single-treatment correction sets a high bar in the physician preference conversation. Cohorts of n=8 per arm leave meaningful statistical uncertainty in either direction.

#9. CMPX — Compass Therapeutics Inc.

THE CATALYST
Event: CTX-009 — Phase 2/3 Full Results (PFS/OS) in 2L Biliary Tract Cancer
Date: Apr 2026 (Est.)
FDA Status: Fast Track Designation (FTD)
BSI: 7.41/10

Boston-based Compass Therapeutics develops multispecific antibodies targeting tumor microenvironment pathways. A Merck collaboration provides Keytruda for CTX-009 combination studies. In April 2026, FDA granted Orphan Drug Designation for CTX-009 in biliary tract cancer (BTC; cancers of the bile ducts and gallbladder). COMPANION-002 enrollment completed August 2024; interim ORR data was positive in April 2025. The pipeline also includes CTX-8371 and CTX-10726 in Phase 1.

📈 The Setup: Volume spiked to 3.1x average this week — the market is front-running the PFS/OS data estimated for April 2026, which is triggered by pre-specified event counts rather than a calendar date. CTX-009 is a DLL4 x VEGF-A bispecific antibody (a dual-targeting molecule that simultaneously blocks DLL4, a Notch signaling ligand driving tumor blood vessel development, and VEGF-A, the principal angiogenesis promoter — cutting off two distinct vascular growth pathways at once). In COMPANION-002 (randomized Phase 2/3, N=150), CTX-009 plus paclitaxel produced a 17.1% ORR including one complete response versus 5.3% for paclitaxel alone in second-line BTC — a randomized controlled separation, not a single-arm comparison to historical data. BTC has no approved non-chemotherapy options for the ~85% of patients without FGFR2 or IDH1 mutations; CTX-009 is biomarker-agnostic by design, targeting the vascular biology that drives BTC regardless of mutation status. The PFS/OS readout now determines whether that ORR advantage translates to survival benefit.

✅ The Edge: A randomized 17.1% vs. 5.3% ORR is a clean controlled signal, not a historical comparison. Biomarker-agnostic design covers the majority of BTC patients that pemigatinib and ivosidenib don't reach. Orphan Drug Designation provides seven years of market exclusivity post-approval.

⚠️ The Risk: ORR benefit hasn't always translated to OS in biliary tract cancer — ramucirumab produced PFS gains without OS improvement in BTC, the cautionary precedent every reviewer will reach for. FDA increasingly views OS as the approval standard in GI oncology, and a PFS-only signal may require a longer confirmatory study. The 2L BTC population is roughly 3,000 U.S. patients per year, limiting peak commercial upside.

#10. PALI — Palisade Bio Inc.

THE CATALYST
Event: PALI-2108 — Phase 1b Conference Presentation at DDW in Moderate-to-Severe Ulcerative Colitis
Date: May 05, 2026
BSI: 7.39/10

Carlsbad, California-based Palisade Bio develops gut-targeted prodrug therapies for IBD (inflammatory bowel disease; chronic immune-driven inflammation of the digestive tract) through an exclusive worldwide license with Giiant Pharma. The Crohn's & Colitis Foundation's IBD Ventures program made an equity investment in January 2026. An April 2026 master services agreement with Iterative Health — accompanied by a $3M stock purchase — establishes a real-world data partnership for Phase 2 trial design. Phase 1b data was first presented at ECCO in February 2026; DDW is the translational follow-on.

📈 The Setup: Ten-plus years of cash runway is the structural differentiator here — Palisade can run a properly powered Phase 2 on its own terms without a cash clock forcing decisions. PALI-2108 is a PDE4 inhibitor prodrug (a precursor molecule activated exclusively by β-glucuronidase, a bacterial enzyme present in the ileal and colonic microbiome, concentrating PDE4 inhibition — which elevates intracellular cAMP to suppress inflammation — in the gut while sparing systemic circulation). In the Phase 1b cohort (N=5 moderate-to-severe UC patients), 100% achieved clinical response within seven days and 40% achieved remission, with colon biopsies confirming suppression of TNF-α, JAK-STAT, NF-κB, MAPK, and TGF-β pathways locally — without peripheral immune effects. No marketed oral UC therapy is colon-selective: tofacitinib (Xeljanz, a JAK inhibitor) and vedolizumab (Entyvio) both carry systemic immunosuppression burdens. The DDW poster will present RNA-seq (gene expression profiling from biopsy tissue) data that either confirms consistent target engagement across patients or exposes variability in the microbiome-dependent activation.

✅ The Edge: No colon-targeted PDE4 inhibitor is on the market — the localized mechanism avoids the infection, cardiovascular, and malignancy signals that limit JAK inhibitors and biologics. Over a decade of runway means no pressure to out-license or dilute before Phase 2 data matures.

⚠️ The Risk: N=5 is a safety cohort, not a signal dataset — one non-responder changes the response rate materially, and β-glucuronidase activity varies based on individual microbiome composition and antibiotic history. FDA has no approved precedent for microbiome-dependent prodrug activation and will likely require PK/PD bridging before clearing a Phase 2/3 design. This is a conference presentation from five patients.

WATCHLIST — #11 through #20

#11. SRPT — Sarepta Therapeutics Inc. [Neuromuscular]

Price: $21.17 | Cap: $2.22B | Cash: $1.10B | RSI: 47.5 | Momentum: +23.4%
AMONDYS 45 (casimersen) + VYONDYS 53 (golodirsen) — sNDA Submission in Duchenne Muscular Dystrophy (Apr 2026 (Est.))
BSI: 7.22/10

The Intel: Sarepta is converting accelerated approvals to full approval for its exon 45 and exon 53 skipping ASOs (antisense oligonucleotides; synthetic molecules that redirect faulty gene splicing to restore partial dystrophin production) in Duchenne muscular dystrophy — the regulatory transition FDA built for this drug cohort. The ESSENCE real-world dataset anchors the conversion case, and neither casimersen nor golodirsen faces a competitor in their respective mutation subsets. The risk is heightened post-accelerated-approval scrutiny: FDA has pushed back on rare disease sNDA conversions more aggressively in recent reviews, and the evidentiary bar for demonstrating clinical benefit beyond biomarker improvement is higher than it was when these drugs first received accelerated approval.

#12. NXTC — NextCure Inc. [Oncology]

Price: $11.00 | Cap: $39.2M | Cash: $32.7M | RSI: 58.4 | Momentum: -5.3%
SIM0505 — Phase 1 Conference Presentation in Solid Tumors (May 29, 2026)
FDA Status: Fast Track Designation (FTD)
BSI: 7.07/10

The Intel: SIM0505 targets SIGLEC-15, a myeloid checkpoint protein expressed on macrophages that suppresses anti-tumor immune activity — a mechanism independent of PD-L1, offering a rationale for combinations in checkpoint-refractory tumors. First patient was dosed October 2025; the ASCO presentation is likely an early safety read and dose-escalation update rather than an efficacy dataset, with a dose optimization study planned for Q2 2026. Human efficacy data here is genuinely limited, and the biology is less clinically validated than the Fast Track Designation might imply. Treat this as a signal-generation phase, not a proof-of-concept readout.

#13. AXSM — Axsome Therapeutics Inc. [CNS/Neurology]

Price: $184.19 | Cap: $9.42B | Cash: $300.8M | RSI: 71.7 | Momentum: +16.7%
AXS-05 (dextromethorphan HBr + bupropion HCl) — PDUFA Regulatory Decision in Alzheimer's Agitation (Apr 2026 (Est.))
FDA Status: Breakthrough Therapy Designation (BTD)
BSI: 7.03/10

The Intel: AXS-05 is an NMDA receptor antagonist combination (blocks overactive glutamate signaling implicated in neurological agitation) that became the first oral therapy to hit the primary endpoint twice in Alzheimer's-associated agitation — a symptom affecting roughly 5 million U.S. patients with no approved treatment. Antipsychotics carry FDA black box warnings for dementia-related psychosis, creating real prescribing space for a non-antipsychotic option. Axsome already holds Auvelity (approved major depression) and Sunosi (narcolepsy), making this an additive launch onto an established commercial base. At $9.4B, the catalyst is lower-asymmetry than the scoring quality suggests — the BSI discount reflects large-cap mechanics rather than drug risk.

#14. BIVI — BioVie Inc. [Neurology]

Price: $1.46 | Cap: $11.0M | Cash: $15.3M | RSI: 58.3 | Momentum: +3.5%
Bezisterim (NE3107) — Phase 2 Conference Presentation in Parkinson's Disease (May 17, 2026)
BSI: 7.00/10

The Intel: BioVie is trading below cash — market cap $11M, cash $15.3M — with Phase 2 Parkinson's topline guided for mid-2026 and a May 17 conference abstract as a preview. Bezisterim inhibits ERK and NF-κB inflammatory signaling pathways (regulators of cellular inflammation and stress responses); prior Phase 2a showed improvement in non-motor symptoms, particularly sleep and fatigue scores. The motor UPDRS (Unified Parkinson's Disease Rating Scale; the standard measure of motor function) outcome is the pivotal question and the one with the most scientific uncertainty given the mechanism's indirect relationship to dopaminergic pathways. Negative dollars are being paid for the Phase 2 dataset — the setup is structurally interesting even if the biology is earlier-stage than the trial phase suggests.

#15. CLYM — Climb Bio Inc. [Hematology]

Price: $8.82 | Cap: $421.3M | Cash: $82.5M | RSI: 71.2 | Momentum: +23.9%
Budoprutug (TNT119) — Phase 1b/2a Design Webcast in Immune Thrombocytopenia (May 05, 2026)
BSI: 6.97/10

The Intel: The May 5 event is a webcast presenting Phase 1b/2a study design — not efficacy data; preliminary results are guided for 2H 2026. Budoprutug is a non-depleting anti-CD19 antibody (binds B cells that produce anti-platelet antibodies without killing them, aiming to reset the autoimmune attack without the infection risk of B-cell depleting therapies like rituximab) in ITP (immune thrombocytopenia; an autoimmune condition where the immune system destroys platelets, causing dangerous bleeding episodes). Human efficacy data is limited; first-in-human flag means this is early. At $421M cap with $82.5M cash, the market is paying substantially forward for 2H data. RSI 71 with no imminent data catalyst is a technical caution.

#16. COCP — Cocrystal Pharma Inc. [Infectious Disease]

Price: $1.57 | Cap: $21.6M | Cash: $4.9M | RSI: 72.9 | Momentum: +38.9%
CDI-988 — Phase 1b Conference Presentation in Norovirus (Apr 27, 2026)
FDA Status: Fast Track Designation (FTD)
BSI: 6.93/10

The Intel: CDI-988 is a viral RNA polymerase inhibitor (blocks the enzyme that copies norovirus genetic material, halting replication) that would be the first oral antiviral for norovirus — a pathogen causing 685 million acute gastroenteritis cases annually with zero approved treatments. Phase 1b at Emory University began dosing in March 2026; the ICAR abstract will present early safety data from a challenge model. The competitive field is essentially empty, which is the opportunity — but human efficacy data is limited at this stage and the Phase 1b dataset is not pivotal efficacy evidence. The +38.9% momentum spike is front-running an abstract. At $4.9M cash with ~8 months of runway, the binary pressure is real regardless of what the conference shows.

#17. INKT — MiNK Therapeutics Inc. [Cell Therapy]

Price: $14.13 | Cap: $70.2M | Cash: $12.0M | RSI: 76.8 | Momentum: +49.4%
AGENT-797 — Phase 2 Interim Data at ASGCT in COVID-19 ARDS (May 11, 2026)
BSI: 6.71/10

The Intel: AGENT-797 is an allogeneic iNKT cell therapy (off-the-shelf invariant natural killer T cells — a specialized immune cell population that can simultaneously suppress inflammation and promote tissue repair — manufactured from healthy donors without patient-matching) for COVID-19 ARDS. Phase 1 showed 91% 60-day survival, a compelling signal against historical ICU benchmarks. The ASGCT abstract will present Phase 2 interim data; full topline is 2H 2026. The caution: COVID-19 ARDS incidence has declined significantly, the regulatory pathway for iNKT cell therapy has no approved precedent, and the Phase 2 design has multiple scoring components pointing toward scientific and regulatory uncertainty. The +49.4% momentum in a micro-float name reflects trading dynamics; full Phase 2 data remains months away.

#18. ARGX — argenx SE [Immunology]

Price: $828.35 | Cap: $51.4B | Cash: $3.49B | RSI: 91.0 | Momentum: +21.0%
VYVGART (efgartigimod) — PDUFA Regulatory Decision in Myasthenia Gravis (May 10, 2026)
BSI: 6.68/10

The Intel: VYVGART Hytrulo (the subcutaneous formulation of efgartigimod, an FcRn antagonist that lowers disease-causing IgG antibodies by blocking their recycling) already holds FDA approval in AChR-positive generalized myasthenia gravis (gMG; an autoimmune disorder where antibodies against neuromuscular junction receptors cause progressive muscle weakness). This PDUFA covers the ADAPT SERON sNDA — an updated label based on the seronegative subgroup data. Efgartigimod's competitive position is strong against C5 inhibitors and newer rivals like rozanolixizumab. At $51.4B and RSI 91, the label expansion is a commercial refinement on a marketed product; the BSI appropriately discounts catalyst asymmetry at this scale.

#19. ALXO — ALX Oncology Holdings Inc. [Oncology]

Price: $1.68 | Cap: $221.1M | Cash: $172.2M | RSI: 30.2 | Momentum: -21.9%
Zanidatamab + Evorpacept (ALX148) — Phase 1b/2 Data at ESMO Breast Cancer in HER2+ Breast Cancer (May 07, 2026)
BSI: 6.67/10

The Intel: This combination pairs zanidatamab (a bispecific antibody targeting two distinct HER2 epitopes simultaneously; HER2 is a growth factor receptor overexpressed in 15–20% of breast cancers) with evorpacept (a CD47 blocker; CD47 is a "don't eat me" surface signal that cancer cells use to evade macrophage destruction). Prior SABCS data showed benefit concentrated in patients with higher CD47 expression — a patient selection signal that meaningfully narrows the addressable population relative to the broader HER2+ setting. RSI 30 after a -21.9% decline makes this technically oversold heading into ESMO Breast Cancer May 7. Cash covers 27 months of operations. The regulatory pathway for a CD47 inhibitor in breast cancer has no approved precedent, and T-DXd (trastuzumab deruxtecan) has reset the efficacy bar in heavily pretreated HER2+ disease.

#20. OKYO — OKYO Pharma Limited [Ophthalmology]

Price: $1.59 | Cap: $53.8M | Cash: $6.3M | RSI: 50.7 | Momentum: -1.9%
Urcosimod (OK-101) — Phase 2a Conference Presentation at ARVO in Neuropathic Corneal Pain (May 03, 2026)
FDA Status: Fast Track Designation (FTD)
BSI: 6.48/10

The Intel: Neuropathic corneal pain (NCP; chronic pain from damaged corneal nerves, often arising post-LASIK or after prolonged contact lens use, distinct from and unresponsive to standard dry eye treatment) has no FDA-approved therapy. Urcosimod is a topical ChemR23 agonist (activates a G protein-coupled receptor that mediates resolution of inflammation and nerve sensitization in corneal tissue), directly targeting the pain mechanism rather than surface inflammation. March 2026 Phase 2a data showed meaningful quality-of-life improvement versus placebo. ARVO will present the fuller dataset. OKYO is UK-domiciled, dual-listed on Nasdaq and London AIM; cash of $6.3M with zero stated runway months is a financing red flag independent of data outcome. The endpoint definition challenge — FDA defining approval criteria for a subjective pain indication with no approved comparator — remains the structural regulatory hurdle.

The Strategist's Take

The single most interesting disconnect in this week's scan is EDSA at BSI 7.97 and a $43M market cap. No drug has ever received FDA approval for ARDS. Paridiprubart completed a 278-patient randomized Phase 3 that cut 28-day mortality from 33% to 24%. That is a 27% relative risk reduction in a disease that kills people reliably despite the best ICU care medicine can deliver. The ATS May 20 presentation adds the subgroup analyses and safety data that turn a topline into a regulatory narrative — and BARDA's selection of this program for a general ARDS platform trial, funded by the U.S. government, is not a small signal. At current prices, near-zero volume, and a -33% momentum reading, the market is not paying attention. That may be warranted if the subgroup data is messier than the topline implies. But the risk-reward here deserves serious attention before ATS, not after.

RLAY is the name that deserves the most caution relative to its positioning. Sixty-two percent in three weeks, $2.88B market cap, two months of cash, and the May 20 catalyst is a vascular anomaly poster with approximately 20 patients. The ReDiscover-2 Phase 3 breast cancer trial is the real thesis — a genuinely interesting mutant-selective PI3Kα asset with BTD in a large indication. But that readout isn't May 20. The capital raise that must happen before summer is not priced into the current momentum. If it occurs post-catalyst on weakness, the dilution is larger than the current share count suggests.

CMPX is the most time-sensitive name in the entire scan. The Phase 2/3 COMPANION-002 PFS/OS data is estimated for April 2026 — the database could lock any day. The 3.1x volume spike confirms the market already knows this. The prior randomized ORR of 17.1% versus 5.3% for paclitaxel in biliary tract cancer is a clean signal, but the OS question determines the regulatory path. Ramucirumab's failure to improve OS in BTC despite PFS benefit is the cautionary tale every reviewer will reference. That answer is in the event count accumulating right now.

MNKD at BSI 8.55 remains the cleanest setup in the scan: an approved product generating revenue, Phase 3 pediatric noninferiority data in hand, 48 months of runway, and a platform diversifying into cardiology via Furoscix. RSI 81.7 reflects recent momentum; there may be a better entry window between now and May 29 if the broader XBI softens on macro noise. The 52-week HbA1c durability data is the legitimate remaining concern — but FDA already decided the 26-week window was the bar that mattered, and MannKind cleared it.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.2 | Generated: 2026-04-17T10:19:55.081980